Results 211 to 220 of about 564,426 (377)

Re: "Role of the herbicide atrazine in the development of non-Hodgkin`s lymphoma" by S Hoar Zahm, DD Weisburger, KP Kantor, FF Holmes, A Blair. Scand J Work Environ Health 1993; 19:108-14.

, 1994
Paolo Crosignani, Franco Berrino
openalex   +1 more source

Bone marrow staging of patients with non-Hodgkin lymphoma by flow cytometry [PDF]

, 2000
Peter Duggan, David Easton, Joanne Luider, Iwona Auer   +3 more
openalex   +1 more source

Hodgkin lymphoma: 2018 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2018
S. Ansell
semanticscholar   +1 more source

Anaplastic large cell lymphoma in children and adolescents

British Journal of Haematology, EarlyView.
Summary Anaplastic lymphoma kinase (ALK)‐positive anaplastic large‐cell lymphoma (ALCL) accounts for >95% of ALCL cases in children and adolescents. The first description of ALCL as a CD30‐positive lymphoma in 1985 was followed by the detection of chromosomal translocations involving the ALK gene at chromosome 2p23.
Eric J. Lowe, Wilhelm Woessmann
wiley   +1 more source

Prognostic factors in non-Hodgkin lymphomas [PDF]

, 2000
Karin Zattar Cecyn, José Salvador Rodrigues de Oliveira, Antonio C. Alves, Maria Regina Régis Silva, J Kerbauy   +4 more
openalex   +1 more source

Cutaneous Hodgkin’s lymphoma

South Asian Journal of Cancer, 2017
Asawari Anant Ambekar, Chitralekha S Soman   +1 more
openaire   +4 more sources

Non-Hodgkin lymphoma

Medicine, 2016
Brad S. Kahl, Grzegorz S. Nowakowski, David T. Yang   +2 more
semanticscholar   +1 more source

Copanlisib in combination with rituximab and bendamustine for transplant‐ineligible relapsed/refractory diffuse large B‐cell lymphoma patients: Results from the phase II multicentre FIL Copa‐BR trial from Fondazione Italiana Linfomi (FIL)

British Journal of Haematology, EarlyView.
A phase II, single‐arm, multicentre trial was conducted by Fondazione Italiana Linfomi (FIL) to investigate the combination of copanlisib plus rituximab and bendamustine (copa‐BR) in transplant‐ and chimeric antigen receptor (CAR)‐T‐ineligible relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). Thirty‐seven patients were enrolled.
Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, Luigi Marcheselli, Samantha Deianira Dattoli, Margherita Vannucchi, Delia Rota‐Scalabrini, Alessandra Tucci, Guido Gini, Giuseppe Tarantini, Donato Mannina, Annalisa Arcari, Arcangelo Liso, Elisabetta Scarpa, Dario Marino, Michele Spina, Ausilia Gorgone, Nicola Di Renzo, Salvatrice Mancuso, Luigi Petrucci, Agostino Tafuri, Barbara Botto, Francesca Bonello, Elisa Santambrogio, Umberto Vitolo   +24 more
wiley   +1 more source

Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Update on Biology and Treatment. [PDF]

Hematol Oncol
Borchmann P, Eichenauer DA, Frigola G, Campo E.   +3 more
europepmc   +1 more source

The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B‐cell lymphomas

British Journal of Haematology, EarlyView.
Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous incidence of relapse and increasing resistance to therapy. Novel immunotherapy approaches are needed.
Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, Max J. Gordon, James D. Phelan, Jagan R. Muppidi, Atekelt Tadese, Sarah Evans, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski   +11 more
wiley   +1 more source